New treatment for peanut allergies shows promise

Adjust Comment Print

Zacks Investment Research raised shares of Aimmune Therapeutics from a "hold" rating to a "buy" rating and set a $34.00 target price on the stock in a research report on Wednesday, November 8th. Therefore 100% are positive. Aimmune Therapeutics has a one year low of $15.97 and a one year high of $42.00. The stock was sold at an average price of $37.00, for a total transaction of $138,750.00. Aimmune Therapeutics had 5 analyst reports since August 31, 2015 according to SRatingsIntel. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company's stock.

Now, Aimmune Therapeutics in California, hope their new treatment will be approved to use in the United States later this year, and in Europe next year.

ILLEGAL ACTIVITY WARNING: "Aimmune Therapeutics' (AIMT) "Buy" Rating Reiterated at Cantor Fitzgerald" was first published by Week Herald and is the property of of Week Herald. Roth Capital maintained Aimmune Therapeutics, Inc.

ILLEGAL ACTIVITY NOTICE: "Aimmune Therapeutics' (AIMT) Outperform Rating Reaffirmed at Wedbush" was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. Aimmune Therapeutics has a consensus rating of "Buy" and a consensus price target of $54.22. The stock has "Mkt Outperform" rating by JMP Securities on Monday, September 26. (NASDAQ:AIMT) on Monday, August 31 with "Buy" rating. The firm has "Overweight" rating by Piper Jaffray given on Tuesday, November 17.

Cdk Global Inc (NASDAQ:CDK) had a decrease of 16.57% in short interest. With 451,300 shares average volume, it will take short sellers 6 days to cover their AIMT's short positions. The SI to Cdk Global Inc's float is 2.95%. About 256,734 shares traded. It has outperformed by 2.22% the S&P500.

First National Bank ends relationship with NRA
That follows a move by First National Bank earlier Thursday to end a credit-card promotion with the gun-advocacy group. Since then, survivors of the shooting have joined with students across the country to press for tougher gun laws.


Shares of Aimmune jumped more than 7% in morning trading on Tuesday to trade near $40 per share. For the next year, analysts expect that the business will report earnings of ($2.95) per share, with EPS estimates ranging from ($3.55) to ($2.33). ValuEngine downgraded Aimmune Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, December 1st.

Aimmune Therapeutics Inc. announced long-awaited Phase 3 data for its peanut allergy treatment AR101, revealing the drug met its goal in the PALISADE study. The stock has a market capitalization of $1,892.13, a price-to-earnings ratio of -14.88 and a beta of -0.82.

Over the last few years, investors have been closely watching Aimmune and DBV to see which company could succeed in late-stage trials and be the first to bring a peanut allergy treatment to patients. Aimmune Therapeutics reported earnings per share of ($0.55) in the same quarter last year, which would suggest a negative year-over-year growth rate of 27.3%. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. Over the last three months, insiders sold 134,294 shares of company stock worth $5,097,144. About 1.55 million shares traded or 221.20% up from the average.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Comments